Ribo’s Phase 2 application to the EMA for RBD1119 arrives against a backdrop where roughly one in five patients with stable coronary artery disease suffers a recurrent thrombotic event despite maximal antiplatelet and anticoagulant therapy — a residual risk figure that has barely moved in a decade of incremental dosing adjustments. That stubborn number is precisely the clinical argument RBD1119 is being built around, and the EMA submission is the first formal test of whether European regulators agree the mechanistic rationale warrants a full Phase 2 interrogation.
RBD1119 is an siRNA targeting a component of the coagulation or thrombotic pathway — Ribo positions it as addressing the “root cause” of thromboembolic disease rather than downstream clot formation. The distinction matters for trial design. If the molecule silences its target durably, the Phase 2 will need to demonstrate sustained pathway suppression across dosing intervals, not just acute pharmacodynamic effect. That creates an endpoint architecture closer to inclisiran’s LDL-C suppression model than to traditional anticoagulant dose-finding: trough biomarker levels at month three and six will almost certainly serve as co-primary or primary endpoints before any event-driven signal is attempted. Whether Ribo has powered the Phase 2 to capture bleeding outcomes as a formal safety endpoint — rather than treating them as adverse events — will define how regulators read the benefit-risk data.
Ribo is running parallel siRNA programs in atrial fibrillation and venous thromboembolism alongside the CAD indication, which is either a sign of genuine platform confidence or a capital allocation risk in a therapeutic area where Alnylam, Novartis, and Ionis have already laid deep clinical and regulatory infrastructure. The EMA submission is the European arm of what appears to be a global filing strategy originating from Suzhou, meaning Ribo is deliberately seeking regulatory credibility in a jurisdiction where siRNA precedent is now well established. That choice accelerates scientific scrutiny but also shortens the path to a European partnership or licensing conversation if Phase 2 data cooperate.
The single outcome worth watching here is EMA’s CTA decision timeline — specifically whether the agency requests additional preclinical bleeding data before authorizing the trial, which would signal that the benefit-risk question around this target class remains unresolved even at the design stage.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
